Retatrutide benefits beyond weight loss: liver fat, blood sugar, and blood pressure

The short answer: beyond weight loss, retatrutide trials have shown large drops in liver fat, better blood sugar control in type 2 diabetes, lower blood pressure, lower triglycerides and inflammation markers, and less knee pain in osteoarthritis. In a phase 2 liver substudy, liver fat fell by a relative 82.4% at 24 weeks on the 12 mg dose, versus a 0.3% rise on placebo. [2]

Two caveats run through everything below. Retatrutide is not approved, so none of these is a labeled benefit that FDA has reviewed. And much of the phase 3 data comes from company toplines, while several of the cardiovascular findings are post hoc analyses. This page reports what trials measured. It does not give dosing advice.

What are the benefits of retatrutide?

Weight loss is the headline. In the phase 2 obesity trial, mean weight change at 48 weeks was minus 24.2% on 12 mg versus minus 2.1% on placebo. [1] The phase 3 numbers, by dose and week, are in retatrutide before and after.

The secondary outcomes matter because retatrutide activates three receptors, GIP, GLP-1, and glucagon, and the glucagon arm is something GLP-1-only drugs lack. [1] Here is what each outcome has shown.

Retatrutide and liver fat

This is the most striking secondary result. A substudy of the phase 2 obesity trial enrolled 98 participants with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called fatty liver disease) and at least 10% liver fat. [2]

Mean relative change in liver fat at 24 weeks: [2]

• 1 mg: minus 42.9%
• 4 mg: minus 57.0%
• 8 mg: minus 81.4%
• 12 mg: minus 82.4%
• Placebo: plus 0.3%

By 24 weeks, normal liver fat (under 5%) was reached by 27%, 52%, 79%, and 86% on 1, 4, 8, and 12 mg, and by 0% on placebo. The reductions tracked weight loss, abdominal fat, and measures of insulin sensitivity and lipid metabolism. [2]

What it does not show: this substudy measured liver fat by imaging, not liver scarring by biopsy, and it did not test whether retatrutide prevents cirrhosis or liver events. The fatty liver disease condition page grades the options we track.

Retatrutide and blood sugar (A1C)

Retatrutide lowers HbA1c, the three-month measure of blood sugar. In the phase 2 type 2 diabetes trial, HbA1c fell by 2.02 percentage points at 24 weeks on 12 mg, versus 0.01 on placebo and 1.41 on dulaglutide 1.5 mg, an approved GLP-1 drug. [3]

The phase 3 result is now peer reviewed. In TRANSCEND-T2D-1, 537 adults with type 2 diabetes managed by diet and exercise alone saw HbA1c fall by 1.69, 1.86, and 1.94 percentage points on 4, 9, and 12 mg at 40 weeks, versus 0.81 on placebo, with no severe hypoglycemia reported. [4] In TRIUMPH-2, which enrolled people with obesity and type 2 diabetes, company toplines report A1C reductions of up to 1.6 percentage points at 80 weeks. [6] The type 2 diabetes condition page grades the options we track.

Retatrutide and blood pressure

In TRIUMPH-3, adults with severe obesity and established cardiovascular disease on the 12 mg dose saw systolic blood pressure fall by an average of 9.3 mmHg. [6] TRIUMPH-1 also reported significant improvement in systolic blood pressure from baseline, without giving the figure in its topline. [5]

A 2026 meta-analysis of randomized trials pooled the earlier data and estimated average reductions of 6.79 mmHg systolic and 2.46 mmHg diastolic. [7] That is a meaningful change, although heart rate goes up on retatrutide, as the phase 2 obesity trial showed, which is one reason the cardiovascular picture is not settled. [1]

Cholesterol, triglycerides, and inflammation

The same meta-analysis found lower total cholesterol, LDL cholesterol, and triglycerides, with no significant change in HDL cholesterol. [7] In TRIUMPH-3, the 12 mg dose cut triglycerides by 37.0%, non-HDL cholesterol by 16.5%, and high-sensitivity C-reactive protein (hsCRP), a marker of inflammation, by 51.2%. [6]

A post hoc analysis of the two phase 2 trials found reductions in atherogenic particles: apolipoprotein B fell by up to 21.4% in the diabetes trial and 24.2% in the obesity trial, and hsCRP fell by 54.8% in the obesity trial but not significantly in the diabetes trial. [8] Post hoc means the analysis was done after the trial, so these are signals, not confirmed outcomes. The cardiovascular risk condition page grades the options we track; lower markers are not the same as fewer heart attacks.

Does retatrutide preserve muscle?

It has not been shown to build or preserve muscle. What the data show is that most of the weight lost is fat. In a DXA substudy of the phase 2 diabetes trial, total fat mass fell by 23.2% on 12 mg versus 4.5% on placebo at 36 weeks, and the proportion of lean mass lost relative to total weight lost was similar to other obesity treatments. [9] In other words, retatrutide did not lose a larger share of lean mass despite larger total weight loss, but it did not avoid lean mass loss either.

Retatrutide and knee osteoarthritis pain

TRIUMPH-4 tested retatrutide in people with obesity and knee osteoarthritis. At 68 weeks, WOMAC pain scores fell by up to 4.5 points (75.8%) from a baseline of 6.0, compared with 2.4 points (40.3%) on placebo, alongside significant improvements in physical function. [10] These are company toplines awaiting peer review. See the osteoarthritis condition page for the options we track.

What about heart and kidney protection?

This is the benefit people most want and the one not yet shown. In TRIUMPH-3, cardiovascular events were rarer than expected, and the hazard ratios for major cardiovascular events had confidence intervals that crossed no effect, so the trial neither proves protection nor rules out harm. [6] A dedicated cardiovascular and kidney outcomes trial, TRIUMPH-Outcomes, is under way. [12] A mechanistic kidney trial, TRANSCEND-CKD, randomized 146 adults with overweight or obesity and chronic kidney disease to measure kidney filtration directly. [11]

Weighing the benefits against the unknowns

Every benefit above was measured in trial participants receiving trial product under supervision. None applies to products sold online, which FDA-regulated channels cannot supply because retatrutide is not approved; its status is tracked on the retatrutide regulatory tracker, and there is no lawful price (see retatrutide cost). The trade-offs are covered in retatrutide side effects.

How it stacks up against drugs you can get today is laid out in our tirzepatide vs retatrutide comparison. People comparing it with a growth-hormone approach to abdominal fat can read tesamorelin vs retatrutide. For lawful treatment now, the GLP-1 hub lists approved options, the obesity condition page grades the evidence, and how to get peptides prescribed explains the route. For how clinics use the term, see what peptide therapy means. For the only lawful way to receive retatrutide itself, see how to get retatrutide.